Mary Wilson
Well-known member
Published: July 15, 2021
DOI:https://doi.org/10.1016/S2666-5247(21)00177-4
Wey Wen Lim, Loretta Mak, Gabriel M Leung, Benjamin J Cowling, Malik Peiris
We report here comparative data on SARS-CoV-2 vaccine immunogenicity in health-care workers in Hong Kong who received either the BNT162b2 vaccine (Comirnaty; Fosun–BioNTech) or the inactivated virus (vero cell) vaccine (Coronavac; Sinovac). We collected blood samples before vaccination, before the second dose, and 21–35 days after the second dose. We tested the samples for antibodies to SARS-CoV-2 using an ELISA to detect antibodies that bind to the receptor binding domain of the spike protein, testing ELISA-positive samples for neutralising antibodies with a surrogate virus neutralisation (sVNT) assay, and then a plaque reduction neutralisation test (PRNT) with live SARS-CoV-2 virus.[SUP]1[/SUP][SUP], [/SUP] [SUP]2[/SUP]
We enrolled a cohort of 1442 health-care workers from public and private hospitals and medical clinics in Hong Kong and arranged for longitudinal collection of blood samples after obtaining informed consent. Here we present our preliminary laboratory testing results on 93 participants for whom we have complete data on antibody concentrations before vaccination, after the first dose, and after the second dose.
...
https://www.thelancet.com/journals/...6-5247(21)00177-4/fulltext#articleInformation
DOI:https://doi.org/10.1016/S2666-5247(21)00177-4
Wey Wen Lim, Loretta Mak, Gabriel M Leung, Benjamin J Cowling, Malik Peiris
We report here comparative data on SARS-CoV-2 vaccine immunogenicity in health-care workers in Hong Kong who received either the BNT162b2 vaccine (Comirnaty; Fosun–BioNTech) or the inactivated virus (vero cell) vaccine (Coronavac; Sinovac). We collected blood samples before vaccination, before the second dose, and 21–35 days after the second dose. We tested the samples for antibodies to SARS-CoV-2 using an ELISA to detect antibodies that bind to the receptor binding domain of the spike protein, testing ELISA-positive samples for neutralising antibodies with a surrogate virus neutralisation (sVNT) assay, and then a plaque reduction neutralisation test (PRNT) with live SARS-CoV-2 virus.[SUP]1[/SUP][SUP], [/SUP] [SUP]2[/SUP]
We enrolled a cohort of 1442 health-care workers from public and private hospitals and medical clinics in Hong Kong and arranged for longitudinal collection of blood samples after obtaining informed consent. Here we present our preliminary laboratory testing results on 93 participants for whom we have complete data on antibody concentrations before vaccination, after the first dose, and after the second dose.
...
https://www.thelancet.com/journals/...6-5247(21)00177-4/fulltext#articleInformation